MGS-2525 is under clinical development by Metagone Biotech and currently in Phase I for Chronic Obstructive Pulmonary Disease (COPD). According to GlobalData, Phase I drugs for Chronic Obstructive Pulmonary Disease (COPD) have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MGS-2525’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MGS-2525 is under development for the treatment of idiopathic pulmonary fibrosis (IPF) , bronchiectasis chronic obstructive pulmonary disease. It is administered by oral route. The drug candidate acts by targeting mitogen-activated protein kinase kinase kinase 19 (MAP3K19).
For a complete picture of MGS-2525’s drug-specific PTSR and LoA scores, buy the report here.